AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
uniQure N.V.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG005SSJYG4
22.43▼ 0.68 (-2.94%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
23.11
Day's Range
22.04 – 23.28
52-Week Range
8.73 – 71.50
Volume
881.0K
Avg Volume
2.8M
Share Statistics
Shares Outstanding
Employees
221
Exchange
XNAS
Listed
2014-02-05
Share count as of July 24, 2026

uniQure N.V. (QURE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about uniQure N.V. (QURE)
What is uniQure N.V.'s Market Cap?
uniQure N.V.'s Market Cap is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s Enterprise Value?
uniQure N.V.'s Enterprise Value is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s Price / Sales?
uniQure N.V.'s Price / Sales is 96.7×, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s EV / Revenue?
uniQure N.V.'s EV / Revenue is 74.1×, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s EV / EBITDA?
uniQure N.V.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s Revenue (TTM)?
uniQure N.V.'s Revenue (TTM) is $16.1M, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s Net Income (TTM)?
uniQure N.V.'s Net Income (TTM) is -$252.2M, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s EBITDA?
uniQure N.V.'s EBITDA is -$185.6M, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s Diluted EPS (TTM)?
uniQure N.V.'s Diluted EPS (TTM) is -3.64, based on as-reported figures from SEC (XBRL) filings.
What is uniQure N.V.'s EBITDA Margin?
uniQure N.V.'s EBITDA Margin is -1153.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · QUREAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
License revenues——
Total revenues
YoY growth+11.0%+127.3%+6.6%+61.8%
Operating expenses:
Cost of license revenues
Research and development expenses
Selling, general and administrative expenses
Total operating expenses
% of revenue-884.8%-1388.6%-1020.6%-1464.5%
Other income
Other expense
Loss from operations
% of revenue-893.7%-1283.5%-918.1%-1379.0%
Interest income
Interest expense
Foreign currency (losses) / gains, net
Other non-operating (losses), net
Loss before income tax expense
Income tax expense
Net loss
% of revenue-1387.8%-1502.9%-666.1%-2175.9%
Basic net loss per ordinary share
Diluted net loss per ordinary share